These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 15544537)

  • 1. The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists.
    Hagmann WK
    Curr Top Med Chem; 2004; 4(14):1461-71. PubMed ID: 15544537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The discovery of sulfonylated dipeptides as potent VLA-4 antagonists.
    Hagmann WK; Durette PL; Lanza T; Kevin NJ; de Laszlo SE; Kopka IE; Young D; Magriotis PA; Li B; Lin LS; Yang G; Kamenecka T; Chang LL; Wilson J; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LA; Kidambi U; Lyons K; Vincent S; Stearns R; Colletti A; Teffera J; Tong S; Fenyk-Melody J; Owens K; Levorse D; Kim P; Schmidt JA; Mumford RA
    Bioorg Med Chem Lett; 2001 Oct; 11(20):2709-13. PubMed ID: 11591507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.
    Chang LL; Yang GX; McCauley E; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2008 Mar; 18(5):1688-91. PubMed ID: 18242984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-aryl-prolyl-dipeptides as potent antagonists of VLA-4.
    Kamenecka TM; Lanza T; de Laszlo SE; Li B; McCauley ED; Van Riper G; Egger LA; Kidambi U; Mumford RA; Tong S; MacCoss M; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2205-8. PubMed ID: 12127538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
    Huryn DM; Konradi AW; Ashwell S; Freedman SB; Lombardo LJ; Pleiss MA; Thorsett ED; Yednock T; Kennedy JD
    Curr Top Med Chem; 2004; 4(14):1473-84. PubMed ID: 15544538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
    Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
    Reger TS; Zunic J; Stock N; Wang B; Smith ND; Munoz B; Green MD; Gardner MF; James JP; Chen W; Alves K; Si Q; Treonze KM; Lingham RB; Mumford RA
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1173-6. PubMed ID: 20022493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of mechanistic drug metabolism studies in support of drug discovery: A case study with an N -sulfonylated dipeptide VLA-4 antagonist in rats.
    Tang W; Stearns RA; Chen Q; Bleasby K; Teffera Y; Colletti A; Hafey M; Evers R; Dean DC; Magriotis PA; Lanza TJ; Lin LS; Hagmann WK; Baillie TA
    Xenobiotica; 2008 Feb; 38(2):223-37. PubMed ID: 18197560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery of acylated beta-amino acids as potent and orally bioavailable VLA-4 antagonists.
    Lin LS; Kopka IE; Mumford RA; Magriotis PA; Lanza T; Durette PL; Kamenecka T; Young DN; de Laszlo SE; McCauley E; Riper GV; Kidambi U; Egger LA; Tong X; Lyons K; Vincent S; Stearns R; Colletti A; Teffera Y; Fenyk-Melody J; Schmidt JA; MacCoss M; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):611-4. PubMed ID: 11844683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of VLA-4 antagonists.
    Tilley JW; Chen L; Sidduri A; Fotouhi N
    Curr Top Med Chem; 2004; 4(14):1509-23. PubMed ID: 15544541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A small molecule alpha4beta1/alpha4beta7 antagonist differentiates between the low-affinity states of alpha4beta1 and alpha4beta7: characterization of divalent cation dependence.
    Egger LA; Cao J; McCallum C; Kidambi U; Van Riper G; McCauley E; Mumford RA; Lanza TJ; Lin LS; de Laszlo SE; Young DN; Yang G; Dean DC; Raab CE; Wallace MA; Jones AN; Hagmann WK; Schmidt JA; Pepinsky RB; Scott DM; Lee WC; Cornebise MA; Detmers PA
    J Pharmacol Exp Ther; 2003 Sep; 306(3):903-13. PubMed ID: 12766251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substituted 3-amino biaryl propionic acids as potent VLA-4 antagonists.
    Kopka IE; Lin LS; Mumford RA; Lanza T; Magriotis PA; Young D; DeLaszlo SE; MacCoss M; Mills SG; Van Riper G; McCauley E; Lyons K; Vincent S; Egger LA; Kidambi U; Stearns R; Colletti A; Teffera Y; Tong S; Owens K; Levorse D; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2415-8. PubMed ID: 12161146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of unique VLA-4 antagonists from a combinatorial library.
    de Laszlo SE; Li B; McCauley E; Van Riper G; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):685-8. PubMed ID: 11844701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists.
    Li B; de Laszlo SE; Kamenecka TM; Kopka IE; Durette PL; Lanza T; MacCoss M; Tong S; Mumford RA; McCauley ED; Van Riper G; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Aug; 12(16):2141-4. PubMed ID: 12127523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
    Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
    Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of acid surrogates toward potency of VLA-4 antagonist.
    Venkatraman S; Lim J; Cramer M; Gardner MF; James J; Alves K; Lingham RB; Mumford RA; Munoz B
    Bioorg Med Chem Lett; 2005 Sep; 15(18):4053-6. PubMed ID: 16039122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
    Chiba J; Iimura S; Yoneda Y; Watanabe T; Muro F; Tsubokawa M; Iigou Y; Satoh A; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2007 Feb; 15(4):1679-93. PubMed ID: 17194595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
    Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-isonicotinoyl-(L)-4-aminophenylalanine derivatives as tight binding VLA-4 antagonists.
    Doherty GA; Yang GX; Borges E; Tong S; McCauley ED; Treonz KM; Van Riper G; Pacholok S; Si Q; Koo GC; Shah K; Mumford RA; Hagmann WK
    Bioorg Med Chem Lett; 2003 Jun; 13(11):1891-5. PubMed ID: 12749892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
    Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ
    Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.